Biotech and Pharmaceuticals
Omicron BA.2 subvariant will soon dominate in U.S., but Fauci doesn’t expect another surge
Dr. Anthony Fauci speaks about the Omicron coronavirus variant during a press briefing at the White House in Washington, December 1, 2021. Kevin Lamarque | Reuters Omicron’s more contagious subvariant, BA.2, has more than doubled in prevalence over the past two weeks in the U.S. and now represents more than 34% of Covid-19 infections that […]
Read More
Moderna Covid vaccine for kids under 6 years old was up to 44% effective against omicron infection
With her husband Stephen by her side Erin Shih hugs her children Avery 6, and Aidan, 11, after they got their second Moderna COVID-19 vaccines at Kaiser Permanente Los Angeles Medical Center on Friday, June 25, 2021. Sarah Reingewirtz | MediaNews Group | Getty Images Moderna’s two-dose Covid vaccine was about 44% effective at preventing […]
Read More
Omicron’s ‘stealth’ subvariant BA.2 could go ‘wild’ in Europe before going global, top epidemiologist says
Doctor Immanuel Hardtmann holds a syringe with the vaccine Moderna in a temporary vaccination center inside the Excursion boat Alexander von Humboldt on the first day of the #HierWirdGeimpft (Get Vaccinated Here) Covid-19 vaccination campaign on September 13, 2021 in Berlin, Germany. Carsten Koall | Getty Images News | Getty Images LONDON — While war […]
Read More
AstraZeneca takes stake in a start-up that helps doctors conduct clinical trials virtually
Medical syringes and small figurines of people are seen in front of the AstraZeneca logo displayed on a screen. On Saturday, March 26, 2021, in Dublin, Ireland. NurPhoto | NurPhoto | Getty Images LONDON — AstraZeneca said Wednesday it has invested in Huma, a U.K.-based medical technology start-up, as part of a broader commercial tie-up […]
Read More
Maverick Ventures’ Ambar Bhattacharyya on the future of health care
Ambar Bhattacharyya, managing director at Maverick Ventures Maverick Ventures Ambar Bhattacharyya is managing director at Maverick Ventures, a $400 million venture capital fund based in San Francisco which invests in health start-ups. His health-care portfolio firms include six IPOs and four unicorns (start-ups valued at $1 billion or more). Bhattacharyya — who currently sits on […]
Read More
Pfizer to supply 4 million Covid antiviral treatments to poorer nations through UNICEF
Paxlovid, a Pfizer’s coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer | Handout | via Reuters Pfizer will supply up to 4 million courses of its oral Covid-19 treatment to dozens of poorer nations under an agreement with the United […]
Read More
FDA advisory committee to discuss future of Covid boosters
A nurses fills up syringes for patients as they receive their coronavirus disease (COVID-19) booster vaccination during a Pfizer-BioNTech vaccination clinic in Southfield, Michigan, September 29, 2021. Emily Elconin | Reuters A Food and Drug Administration advisory committee will meet next month to discuss the future of Covid-19 booster shots in the U.S., and whether […]
Read More
Investors see growth opportunity in Femtech devoted to women’s health
To Dr. Connie Lehman, a breast cancer scan is like a fingerprint that provides clues for developing personalized medical care. “There is so much information in every digital image of a woman’s breast tissue, and the deep learning technology can extract that and predict the future and in ways we haven’t been able to […]
Read More
Here’s how Covid-19 transitions from a pandemic to endemic
It’s been two years since Covid-19 crept across the globe, battered the U.S. economy and wreaked havoc on health-care systems unprepared to defend themselves against the novel pathogen. Now, as the latest wave of infections driven by the fast-spreading omicron variant rapidly subsides, many are beginning to question: Is Covid-19 becoming endemic? “There’s a high […]
Read More
Pfizer CEO Albert Bourla received $24.3 million in total compensation for 2021
Pfizer CEO Albert Bourla addresses a press conference after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021. John Thys | Pool | Reuters Pfizer CEO Albert Bourla received $24.3 million in total compensation for 2021, a 15% increase […]
Read More